Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Glioblastoma × Pharmacogenomic Testing × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 4 Rectal Neoplasms 3 Colorectal Neoplasms 3 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Melanoma 2 Lymphoma, Mantle-Cell 2 Lymphoma 2 Colonic Neoplasms 2 Uveal Melanoma 1 Thyroid Neoplasms 1 Thyroid Cancer, Papillary 1 Squamous Cell Carcinoma of Head and Neck 1 Solitary Fibrous Tumor, Pleural 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic Neoplasms 1 Neurotoxicity Syndromes 1 Neoplasms, Plasma Cell 1 Neoplasm Metastasis 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Mesothelioma, Malignant 1 Malignant Tumor of Ill-defined Site 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Large-Cell, Immunoblastic 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma, Extranodal NK-T-Cell 1

Interventions

Temozolomide 140 Bevacizumab 80 Radiotherapy 69 Magnetic Resonance Spectroscopy 22 Radiation 18 Irinotecan 18 pembrolizumab 17 Lomustine 16 Carmustine 15 Surgical Procedures, Operative 13 Nivolumab 11 Erlotinib Hydrochloride 11 sargramostim 9 Thalidomide 9 Specimen Handling 9 Chemotherapy, Adjuvant 9 Aminolevulinic Acid 9 Carboplatin 8 Cilengitide 7 Sunitinib 6 Immunoglobulin G 6 Etoposide 6 Disulfides 6 Cyclophosphamide 6 antineoplaston AS 2-1 5 antineoplaston A10 5 Radiotherapy, Intensity-Modulated 5 Radiosurgery 5 Metformin 5 Imatinib Mesylate 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03216499 2022-05-09

PT2385

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed

24 enrolled 11 charts

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡